Current Rheumatology Reviews

Dr. Serena Guiducci  
Department of Biomedicine, Division of Rheumatology
University of Florence
Florence
Italy

Back

Suppression of Erosive Arthritis by NF-κB Inhibitors

Author(s): Tetsuo Kubota, Kazuo Umezawa.

Abstract:

Excess activation of NF-kappa B is often involved in inflammation and cancer progression. We have developed a specific NF-kappa B inhibitor dehydroxyepoxyquinomicin (DHMEQ). It binds to the specific cysteine residue of Rel family proteins. DHMEQ inhibited cytokine secretions and osteoclastogenesis in cultured macrophages. It inhibited various animal models of inflammation and cancer. Especially, it inhibited type 2-induced rheumatoid arthritis without any toxicity in mice. It also decreased the number of osteoclasts in the inflammatory tissues. Thus, excess activation of NF-kappa B is essential for rheumatoid arthritis, and DHMEQ is a candidate of new anti-rheumatoid chemotherapeutic agent.

Keywords: NF-kappa B, DHMEQ, macrophage, osteoclast, NFATc1, chemotherapy

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 7
ISSUE: 4
Year: 2011
Page: [275 - 281]
Pages: 7
DOI: 10.2174/157339711798221077
Price: $58